tetano
Editor, Senior Moderator
Vaccine
. 2023 Jun 6;S0264-410X(23)00495-4.
doi: 10.1016/j.vaccine.2023.04.069. Online ahead of print. Cost-effectiveness of routine annual influenza vaccination by age and risk status
Ellen Kim DeLuca[SUP] 1 [/SUP], Acham Gebremariam[SUP] 2 [/SUP], Angela Rose[SUP] 2 [/SUP], Matthew Biggerstaff[SUP] 3 [/SUP], Martin I Meltzer[SUP] 4 [/SUP], Lisa A Prosser[SUP] 5 [/SUP]
Affiliations
Background: The epidemiology of circulating seasonal influenza strains changed following the 2009 pandemic influenza A(H1N1). A universal influenza vaccination recommendation has been implemented and new vaccine types have become available post-2009. The objective of this study was to evaluate the cost-effectiveness of routine annual influenza vaccination in the context of this new evidence.
Methods: A state transition simulation model was constructed to estimate the health and economic outcomes of influenza vaccination compared to no vaccination for hypothetical US cohorts stratified by age and risk status. Model input parameters were derived from multiple sources, including post-2009 vaccine effectiveness data from the US Flu Vaccine Effectiveness Network. The analysis used societal and healthcare sector perspectives and a one-year time horizon, except permanent outcomes were also included. The primary outcome was the incremental cost-effectiveness ratio (ICER) in dollars per quality-adjusted life years (QALYs) gained.
Results: Compared to no vaccination, vaccination yielded ICERs lower than $95,000/QALY for all age and risk groups, except for non-high-risk adults 18-49 years ($194,000/QALY). Vaccination was cost-saving for adults ≥50 years at higher risk for influenza-related complications. Results were most sensitive to changes in the probability of influenza illness. Performing the analysis from the healthcare sector perspective, excluding vaccination time costs, delivering vaccinations in lower-cost settings, and including productivity losses improved the cost-effectiveness of vaccination. Sensitivity analysis revealed that vaccination remains below $100,000/QALY for older persons ≥65 years at vaccine effectiveness estimates as low as 4 %.
Conclusions: Cost-effectiveness of influenza vaccination varied by age and risk status and was less than $95,000/QALY for all subgroups, except for non-high-risk working-age adults. Results were sensitive to the probability of influenza illness and vaccination was more favorable under certain scenarios. Vaccination for higher risk subgroups resulted in ICERs below $100,000/QALY even at low levels of vaccine effectiveness or circulating virus.
Keywords: Comparative effectiveness; Cost-effectiveness; Economic evaluation; Influenza; Vaccination.
. 2023 Jun 6;S0264-410X(23)00495-4.
doi: 10.1016/j.vaccine.2023.04.069. Online ahead of print. Cost-effectiveness of routine annual influenza vaccination by age and risk status
Ellen Kim DeLuca[SUP] 1 [/SUP], Acham Gebremariam[SUP] 2 [/SUP], Angela Rose[SUP] 2 [/SUP], Matthew Biggerstaff[SUP] 3 [/SUP], Martin I Meltzer[SUP] 4 [/SUP], Lisa A Prosser[SUP] 5 [/SUP]
Affiliations
- PMID: 37291022
- DOI: 10.1016/j.vaccine.2023.04.069
Background: The epidemiology of circulating seasonal influenza strains changed following the 2009 pandemic influenza A(H1N1). A universal influenza vaccination recommendation has been implemented and new vaccine types have become available post-2009. The objective of this study was to evaluate the cost-effectiveness of routine annual influenza vaccination in the context of this new evidence.
Methods: A state transition simulation model was constructed to estimate the health and economic outcomes of influenza vaccination compared to no vaccination for hypothetical US cohorts stratified by age and risk status. Model input parameters were derived from multiple sources, including post-2009 vaccine effectiveness data from the US Flu Vaccine Effectiveness Network. The analysis used societal and healthcare sector perspectives and a one-year time horizon, except permanent outcomes were also included. The primary outcome was the incremental cost-effectiveness ratio (ICER) in dollars per quality-adjusted life years (QALYs) gained.
Results: Compared to no vaccination, vaccination yielded ICERs lower than $95,000/QALY for all age and risk groups, except for non-high-risk adults 18-49 years ($194,000/QALY). Vaccination was cost-saving for adults ≥50 years at higher risk for influenza-related complications. Results were most sensitive to changes in the probability of influenza illness. Performing the analysis from the healthcare sector perspective, excluding vaccination time costs, delivering vaccinations in lower-cost settings, and including productivity losses improved the cost-effectiveness of vaccination. Sensitivity analysis revealed that vaccination remains below $100,000/QALY for older persons ≥65 years at vaccine effectiveness estimates as low as 4 %.
Conclusions: Cost-effectiveness of influenza vaccination varied by age and risk status and was less than $95,000/QALY for all subgroups, except for non-high-risk working-age adults. Results were sensitive to the probability of influenza illness and vaccination was more favorable under certain scenarios. Vaccination for higher risk subgroups resulted in ICERs below $100,000/QALY even at low levels of vaccine effectiveness or circulating virus.
Keywords: Comparative effectiveness; Cost-effectiveness; Economic evaluation; Influenza; Vaccination.